Abstract: The present invention relates to methods for treatment of tumors and other diseases in a mammal comprising administration of antibodies specific for Macrophage-Stimulating Protein Receptor (“MSP-R” or “RON”). The present invention further provides for compositions comprising antibodies or antibody fragments specific for RON, including human antibodies, that inhibit RON activation.

Abstract: The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VIE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine ceH indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the prectinical development since its anti-tumor activity can be tested extensively in several mouse models.

Abstract: Chimeric and humanized monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.

Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of a flt-1 receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.

Abstract: The present invention provides methods of stimulating or inhibiting intracellular phosphorylation of tyrosine by a heparin-binding receptor which comprises contacting a cell having on its surface the heparin-binding receptor with a phosphorothioate oligonucleotide moiety of suitable length and base composition, such phosphorothioate oligonucleotide moiety being present in an effective amount. The invention further provides a method of inhibiting the formation of blood vessels in a subject which comprises administering to the subject an amount of a phosphorothioate oligonucleotide moiety of suitable length and base composition. The invention also provides a method of inhibiting proliferation of cells having a malignant phenotype in a subject which comprises administering to the subject an amount of a phosphorothioate oligonucleotide moiety of suitable length and base composition.

Abstract: Muteins of IL-6 and truncated IL-6 are prepared by recombinant DNA techniques. In the muteins, the cysteine residues that occur at positions, or at positions corresponding to positions, 45 and 51 of mature, native IL-6 have been replaced by other amino acids. The cysteine residues that occur at positions, or at positions corresponding to positions, 74 and 84 are retained. The molecule has biological activity that is at least comparable to that of native IL-6.